MUC5AC and pancreatic adenocarcinoma: Zhang et al. evaluated the combination of CA19-9 with the serological measurement of MUC5AC in 61 patients with pancreatic adenocarcinoma compared to healthy control patients, patients with choledocholithiasis, and patients with chronic pancreatitis.